After clearing out heart disease drug, Arrowhead maps out obesity development plans

After Arrowhead Pharmaceuticals cleared out its work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both set to enter the clinic in early 2025.

The RNA interference (RNAi) company presented two next-gen candidates during an R&D investor event Aug. 14: Dubbed ARO-INHBE and ARO-ALK7, they are designed to treat obesity and metabolic diseases.